Repligen (NASDAQ:RGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 […]
Repligen (NASDAQ:RGEN – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 […]
Intrust Bank NA lowered its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 9.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,364 shares of the biotechnology company’s stock after selling 136 shares during the period. Intrust Bank NA’s holdings in […]
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
LRT Capital Management LLC raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 9.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,707 shares of the biotechnology company’s stock after purchasing an additional 502 shares during the quarter. LRT Capital Management LLC’s holdings in Repligen were worth $1,026,000 as of its most […]